Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Cyclopentanone ring-cleaved pleuromutilin derivatives.

Springer DM, Bunker A, Luh BY, Sorenson ME, Goodrich JT, Bronson JJ, DenBleyker K, Dougherty TJ, Fung-Tomc J.

Eur J Med Chem. 2007 Jan;42(1):109-13. Epub 2006 Dec 6.

PMID:
17156897
2.

Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.

D'Andrea S, Zheng ZB, Denbleyker K, Fung-Tomc JC, Yang H, Clark J, Taylor D, Bronson J.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2834-9.

PMID:
15911264
3.

Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics.

Pucci MJ, Bronson JJ, Barrett JF, DenBleyker KL, Discotto LF, Fung-Tomc JC, Ueda Y.

Antimicrob Agents Chemother. 2004 Oct;48(10):3697-701.

4.

Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials.

Snyder LB, Meng Z, Mate R, D'Andrea SV, Marinier A, Quesnelle CA, Gill P, DenBleyker KL, Fung-Tomc JC, Frosco M, Martel A, Barrett JF, Bronson JJ.

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4735-9.

PMID:
15324898
5.

In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates.

Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J.

Clin Microbiol Infect. 2003 Dec;9(12):1250-2. No abstract available.

6.

Nocathiacins, new thiazolyl peptide antibiotics from Nocardia sp. I. Taxonomy, fermentation and biological activities.

Li W, Leet JE, Ax HA, Gustavson DR, Brown DM, Turner L, Brown K, Clark J, Yang H, Fung-Tomc J, Lam KS.

J Antibiot (Tokyo). 2003 Mar;56(3):226-31.

7.
8.

In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates.

Valera L, Gradelski E, Huczko E, Washo T, Yigit H, Fung-Tomc J.

J Antimicrob Chemother. 2002 Jul;50(1):140-2. No abstract available.

PMID:
12096023
9.

In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against organisms other than staphylococci.

Clark J, Fung-Tomc JC, Minassian B, Tsai YH, Yang H, Huczko E, Kolek B, Chaniewski S, Ferraro C, Drain R, Gradelski E, Bonner DP.

Antimicrob Agents Chemother. 2002 Apr;46(4):1108-11.

10.

In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci.

Fung-Tomc JC, Clark J, Minassian B, Pucci M, Tsai YH, Gradelski E, Lamb L, Medina I, Huczko E, Kolek B, Chaniewski S, Ferraro C, Washo T, Bonner DP.

Antimicrob Agents Chemother. 2002 Apr;46(4):971-6.

11.

Bactericidal mechanism of gatifloxacin compared with other quinolones.

Gradelski E, Kolek B, Bonner D, Fung-Tomc J.

J Antimicrob Chemother. 2002 Jan;49(1):185-8.

PMID:
11751786
12.

Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci.

Fung-Tomc J, Valera L, Minassian B, Bonner D, Gradelski E.

J Antimicrob Chemother. 2001 Nov;48(5):735-8. No abstract available.

PMID:
11679566
13.

Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.

Gradelski E, Valera L, Bonner D, Fung-Tomc J.

Antimicrob Agents Chemother. 2001 Nov;45(11):3220-2.

14.

Intracellular penetration and bactericidal activity of the novel des-fluoro(6) quinolone, BMS-284756.

Kolek B, Warr G, Bonner D, Fung-Tomc J.

J Antimicrob Chemother. 2001 Sep;48(3):445-6. No abstract available.

PMID:
11533015
15.

Correlation between genotype and phenotypic categorization of staphylococci based on methicillin susceptibility and resistance.

Gradelski E, Valera L, Aleksunes L, Bonner D, Fung-Tomc J.

J Clin Microbiol. 2001 Aug;39(8):2961-3.

16.

Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.

Fung-Tomc J, Gradelski E, Huczko E, Minassian B, Bonner DP.

Int J Antimicrob Agents. 2001 Jul;18(1):77-80.

PMID:
11463531
17.

Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.

Gradelski E, Valera L, Kolek B, Bonner D, Fung-Tomc J.

Int J Antimicrob Agents. 2001 Jul;18(1):43-8.

PMID:
11463525
18.

Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.

Gradelski E, Kolek B, Bonner DP, Valera L, Minassian B, Fung-Tomc J.

Int J Antimicrob Agents. 2001 Feb;17(2):103-7.

PMID:
11165113
19.

Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.

Huczko E, Conetta B, Bonner D, Valera L, Stickle T, Macko A, Fung-Tomc J.

Int J Antimicrob Agents. 2000 Dec;16(4):401-5.

PMID:
11118848
20.

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, Washo T, Gradelski E, Valera L, Bonner DP.

Antimicrob Agents Chemother. 2000 Dec;44(12):3351-6.

21.

Comparative killing rates of fluoroquinolones and cell wall-active agents.

Fung-Tomc JC, Gradelski E, Valera L, Kolek B, Bonner DP.

Antimicrob Agents Chemother. 2000 May;44(5):1377-80.

22.

In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.

Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D.

J Antimicrob Chemother. 2000 Apr;45(4):437-46.

PMID:
10747819
23.

In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole.

Fung-Tomc JC, White TC, Minassian B, Huczko E, Bonner DP.

Diagn Microbiol Infect Dis. 1999 Oct;35(2):163-7.

PMID:
10579098
24.

In vitro activity of a new oral triazole, BMS-207147 (ER-30346)

Fung-Tomc JC, Huczko E, Minassian B, Bonner DP.

Antimicrob Agents Chemother. 1998 Feb;42(2):313-8. Erratum in: Antimicrob Agents Chemother 1998 Apr;42(4):993.

25.

Antibacterial activity of BMS-180680, a new catechol-containing monobactam.

Fung-Tomc J, Bush K, Minassian B, Kolek B, Flamm R, Gradelski E, Bonner D.

Antimicrob Agents Chemother. 1997 May;41(5):1010-6.

26.

Recent developments in pradimicin-benanomicin and triazole antibiotics.

Fung-Tomc JC, Bonner DP.

Expert Opin Investig Drugs. 1997 Feb;6(2):129-45.

PMID:
15989596
27.
28.

Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1996 May;40(5):1289-93.

29.

Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides.

Fung-Tomc JC, Huczko E, Stickle T, Minassian B, Kolek B, Denbleyker K, Bonner D, Kessler R.

Antimicrob Agents Chemother. 1995 Feb;39(2):533-8.

30.

Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa.

Fung-Tomc JC, Huczko E, Banville J, Ménard M, Kolek B, Gradelski E, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):394-9.

31.

Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.

Fung-Tomc JC, Gradelski E, Kolek B, Minassian B, Pucci M, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):386-93.

32.

In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.

Kessler RE, Fung-Tomc J, Kolek B, Minassian B, Huczko E, Gradelski E, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):380-5.

33.

In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.

Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE.

Antimicrob Agents Chemother. 1995 Feb;39(2):295-300.

34.

Susceptibility of United States clinical trial isolates to cefprozil and cefaclor.

Kessler RE, Fung-Tomc JC.

Diagn Microbiol Infect Dis. 1994 Feb;18(2):129-32.

PMID:
8062532
35.

Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations.

Gradelski E, Fung-Tomc J, Huczko E, Kessler RE.

J Antimicrob Chemother. 1993 Nov;32 Suppl B:75-80.

PMID:
8150769
37.

beta-Lactamase parameters of heterogeneously and homogeneously methicillin-resistant Staphylococcus aureus.

Gradelski E, Huczko E, Kessler RE, Bonner DP, Fung-Tomc J.

J Antimicrob Chemother. 1993 Mar;31(3):441-2. No abstract available.

PMID:
8486580
38.

Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays.

Mamber SW, Kolek B, Brookshire KW, Bonner DP, Fung-Tomc J.

Antimicrob Agents Chemother. 1993 Feb;37(2):213-7.

40.

Fluoronaphthyridines and -quinolones as antibacterial agents. 5. Synthesis and antimicrobial activity of chiral 1-tert-butyl-6-fluoro-7-substituted-naphthyridones.

Di Cesare P, Bouzard D, Essiz M, Jacquet JP, Ledoussal B, Kiechel JR, Remuzon P, Kessler RE, Fung-Tomc J, Desiderio J.

J Med Chem. 1992 Oct 30;35(22):4205-13.

PMID:
1433222
41.

Synthesis and antibacterial activity of some novel 6-methyl- and 6-propenyl-substituted carbapenems.

Mastalerz H, Menard M, Ruediger E, Fung-Tomc J.

J Med Chem. 1992 Mar 6;35(5):953-8.

PMID:
1548685
42.

Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.

Bouzard D, Di Cesare P, Essiz M, Jacquet JP, Ledoussal B, Remuzon P, Kessler RE, Fung-Tomc J.

J Med Chem. 1992 Feb 7;35(3):518-25.

PMID:
1738144
43.

The synthesis, antibacterial, and beta-lactamase inhibitory activity of a novel asparenomycin analog.

Bouthillier G, Mastalerz H, Menard M, Fung-Tomc J, Gradelski E.

J Antibiot (Tokyo). 1992 Feb;45(2):240-5.

44.

In vitro and in vivo evaluation of BMY 45243, a new 5-amino-naphthyridone derivative.

Bouzard D, Di Cesare P, Hoffmann P, Fung-Tomc J, Kessler R.

Drugs Exp Clin Res. 1992;18(7):291-4.

PMID:
1338310
45.

In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.

Fung-Tomc J, Huczko E, Kolek B, Thater C, Kessler RE.

Antimicrob Agents Chemother. 1991 Dec;35(12):2652-4.

46.

Emergence of homogeneously methicillin-resistant Staphylococcus aureus.

Fung-Tomc J, Huczko E, Gradelski E, Denbleyker K, Bonner DP, Kessler RE.

J Clin Microbiol. 1991 Dec;29(12):2880-3.

47.

Inability of cephalothin testing to predict cefprozil susceptibility.

Fung-Tomc J, Stickle T, Doyle C, Huczko E, Kessler RE.

J Clin Microbiol. 1991 Nov;29(11):2643-7.

49.

In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.

Fung-Tomc J, Desiderio JV, Tsai YH, Warr G, Kessler RE.

Antimicrob Agents Chemother. 1989 Jun;33(6):906-14.

50.

In vitro and in vivo evaluations of a new broad-spectrum oral cephalosporin, BMY-28232, and its prodrug esters.

Tomatsu K, Masuyoshi S, Hirano M, Kawaguchi H, Oki T, Fung-Tomc J, Desiderio JV, Kessler RE.

Antimicrob Agents Chemother. 1989 Apr;33(4):489-97.

Supplemental Content

Loading ...
Support Center